AUPH
NASDAQ
CA
Aurinia Pharmaceuticals Inc - Common Shares
$15.61
▲ +$0.14
(+0.91%)
Vol 1.3M
12
Quality Score
ok
Deep Check
1/5
fail
Rev ✓
NI ✗
>IPO ✗
Mkt Cap
$2.1B
P/E
27.0
ROE
21.8%
Margin
29.3%
D/E
19.69
Beta
1.53
52W
$7–$17
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
6
Buy
4
Hold
0
Sell
0
Strong Sell
69.2%
Buy Rating
Price Chart
Similar Stocks
About Aurinia Pharmaceuticals Inc - Common Shares
Aurinia Pharmaceuticals (AUPH) — біотехнологічна компанія, що спеціалізується на розробці та комерціалізації ліків для лікування аутоімунних захворювань, зокрема люпус-нефриту. Їхній основний продукт, LUPKYNIS, є першим схваленим FDA пероральним препаратом для лікування цієї хвороби. Компанія має сильну позицію на ринку завдяки фокусу на невирішених медичних потребах у ніші аутоімунних захворювань.
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.22 | $0.26 | +$0.04 |
| Sep 2025 | $0.16 | $0.23 | +$0.07 |
| Jun 2025 | $0.15 | $0.16 | +$0.01 |
| Mar 2025 | $0.10 | $0.16 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $59.9M | $62.5M | $70.0M | $73.5M | $77.1M |
| Net Income | — | $1.4M | $23.3M | $21.5M | $31.6M | $210.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 16.7% | 16.7% | 16.7% | 16.7% | 21.8% | 21.8% |
| P/E (TTM) | 18.87 | 25.92 | 24.92 | 28.59 | 27.24 | 27.02 |
| Net Margin | 30.7% | 23.3% | 23.3% | 23.3% | 29.3% | 29.3% |
| Gross Margin | 89.8% | 89.5% | 89.5% | 89.5% | 88.9% | 88.9% |
| D/E Ratio | 22.50 | 22.50 | 22.50 | 22.50 | 19.69 | 19.69 |
| Current Ratio | 5.23 | 5.23 | 5.23 | 5.23 | 5.76 | 5.76 |
Key Ratios
ROA (TTM)
14.9%
P/S (TTM)
7.91
P/B
3.4
EPS (TTM)
$0.56
CF/Share
$-0.49
Rev Growth 3Y
+72.8%
52W High
$16.54
52W Low
$6.55
$6.55
52-Week Range
$16.54
Financial Health
Free Cash Flow
$45.6M
Net Debt
-$5.4M
Cash
$80.2M
Total Debt
$74.8M
As of Dec 31, 2025
How does AUPH compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AUPH valuation vs Biotechnology peers
P/E ratio
27.0
▲
44%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.9
▼
38%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.4
▲
38%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AUPH profitability vs Biotechnology peers
ROE
21.8%
▲
132%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
29.3%
▲
110%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
88.9%
▲
13%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
14.9%
▲
132%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
AUPH financial health vs Biotechnology peers
D/E ratio
19.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
5.8
▲
30%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
1.5
▲
57%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
AUPH fundamentals radar
AUPH
Peer median
Industry
AUPH profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AUPH vs peers: key metrics
Latest News
No related news yet